Genetics and Genomics of Muscle Postdoctoral Training Program

肌肉遗传学与基因组学博士后培养项目

• 批准号: 9272835
• 负责人: JYOTI K JAISWAL
• 金额: $ 25.24万
• 依托单位: CHILDREN'S RESEARCH INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-05-28 至 2020-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9272835
• 关键词: Genetic; Genomics; Muscle; Training Programs; post-doctoral training

 DESCRIPTION (provided by applicant): A renewal for a training grant (T32) for post-doctoral fellows in Genetics and Genomics of Muscle is described. Training faculty is drawn from Children's National Medical Center, NIH intramural program, and George Washington University. Research and training topics focus on understanding muscle tissue in health and disease (dystrophy and damage), with an emphasis on genome-enabled approaches and translational research. Lab bench-based technological training includes state-of-art research methods such as genomics, proteomics, epigenomics, biomarker discovery and validation, drug development and pre-clinical efficacy and toxicity. This technological bench training is heavily augmented with training in bioinformatics and statistics, and appropriate conduct of research. Unique opportunities for trainees include integration into neuromuscular clinical training at both NIH NINDS and CNMC (2/9 previous awardees), ABMG certification (1/9), and training in clinical trials and outcome measures in the CINRG group and NIH intramural program (2/9). Training in private-public partnerships, industry spin-offs, intellectual property development, and regulatory science are also key strengths of the T32. The T32 program is bolstered through synergism by a strong foundation of federally-funded Center and Core grants on muscle translational research led by Training Faculty that provide rich core facilities and pilot funding opportunities for the T32 fellows. These include a Center of Research Translation (NIAMS P50), National Center for Medical Rehabilitation Research (NICHD/NINDS R24), Research in Pediatric Developmental Pharmacology (NICHD U54), CINRG clinical trial network (NIAMS RO1s and DoD grants on outcome measures), Mouse Pathobiology (NIH OD R26), Intellectual and Developmental Disabilities Research Center (NICHD P30), and pediatrics-focused CTSA (NCATS). The initial award filled all available slots through a highly competitive process, with fellows publishing high impact papers, and all graduates retained in independent academic biomedical research positions, including an endowed chair leading a muscular dystrophy program, and head of a molecular diagnostics laboratory. ~30% of trainees were physician/scientists - a stated goal of the original training program. We will train 2 postdoctoral M.D. trainee and 4 postdoctoral Ph.D. trainees in Yr01; 2 postdoctoral M.D. trainees and 5 postdoctoral Ph.D. trainees in Yrs02 through Yr05. A total of 14 postdoctoral trainees will be appointed to this T-32 program over the 5 year funding cycle. At completion, the T32 postdoctoral fellows will be able to independently complete research projects, collaborate in multi-disciplinary research projects, publish research results, apply for independent funding, and successfully interview in academic, pharmaceutical and biomedical research institutions.

 描述（由申请人提供）：描述了针对肌肉遗传学和基因组学博士后研究员的培训补助金（T32）的更新，培训人员来自儿童国家医疗中心、NIH 校内项目和乔治华盛顿大学。培训主题侧重于了解健康和疾病（营养不良和损伤）中的肌肉组织，重点是基于基因组的方法和基于实验室工作台的转化研究，包括最先进的研究方法，例如。基因组学、蛋白质组学、表观基因组学、生物标志物发现和验证、药物开发以及临床前功效和毒性等方面的培训通过生物信息学和统计学的培训得到了极大的增强，并且为学员提供了独特的研究机会，包括融入神经肌肉领域。 NIH NINDS 和 CNMC 的临床培训（2/9 之前的获奖者）、ABMG 认证（1/9）以及 CINRG 小组和 NIH 的临床试验和结果测量培训校内计划（2/9）。 监管科学也是 T32 的关键优势，T32 计划通过联邦资助的中心和培训学院领导的肌肉转化研究核心拨款的协同作用得到支持，为 T32 研究员提供丰富的核心设施和试点资助机会。其中包括研究翻译中心 (NIAMS P50)、国家医疗康复研究中心 (NICHD/NINDS R24)、儿科发育药理学研究 (NICHD) U54）、CINRG 临床试验网络（NIAMS RO1 和 DoD 对结果测量的资助）、小鼠病理学 (NIH OD R26)、智力和发育障碍研究中心 (NICHD P30) 以及以儿科为重点的 CTSA (NCATS)。所有可用的职位都通过高度竞争的过程进行，研究员发表高影响力的论文，所有毕业生都保留在独立的学术生物医学研究职位，包括一位领导强大的教授的主席营养不良项目和分子诊断实验室负责人，约 30% 的学员是医生/科学家——这是最初培训项目的既定目标。我们将培训 2 名博士后。 第 01 年有 2 名博士后学员和 5 名博士后学员 在 5 年资助期间，共有 14 名博士后学员被任命为 T-32 项目。周期结束后，T32博士后将能够独立完成研究项目、合作开展多学科研究项目、发表研究成果、申请独立研究。资助，并成功面试学术、制药和生物医学研究机构。